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Background: Knowledge about Klinefelter syndrome (KS) has increased substantially 
since its first description almost 80 years ago. A variety of treatment options con-
cerning the spectrum of symptoms associated with KS exists, also regarding aspects 
beyond testicular dysfunction. Nevertheless, the diagnostic rate is still low in relation 
to prevalence and no international guidelines are available for KS.
Objective: To create the first European Academy of Andrology (EAA) guidelines on KS.
Methods: An expert group of academicians appointed by the EAA generated a con-
sensus guideline according to the GRADE (Grading of Recommendations, Assessment, 
Development and Evaluation) system.
Results: Clinical features are highly variable among patients with KS, although com-
mon characteristics are severely attenuated spermatogenesis and Leydig cell impair-
ment, resulting in azoospermia and hypergonadotropic hypogonadism. In addition, 
various manifestations of neurocognitive and psychosocial phenotypes have been 
described as well as an increased prevalence of adverse cardiovascular, metabolic 
and bone-related conditions which might explain the increased morbidity/mortality 
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1  | INTRODUC TION
Klinefelter syndrome (KS) is the most frequent chromosome dis-
order in men, exhibiting a karyotype of 47,XXY. Symptoms in KS 
are highly variable. Nevertheless, frequent characteristics are small 
testes, azoospermia and hypergonadotropic hypogonadism. Also 
neurocognitive and psychosocial manifestations can be seen as well 
as cardiovascular, metabolic and bone-related conditions of adverse 
nature. Generally, morbidity and mortality are increased in KS com-
pared to men with a karyotype of 46,XY. Both hypogonadism and 
genetic effects seem to contribute to this clinical spectrum. Among 
physicians, knowledge about KS regarding diagnosis and treatment 
is distributed unevenly. KS is not fully known to many physicians 
and there is a marked need for a respective improvement of medical 
curricula.
Whereas KS is usually considered in all guidelines dealing with 
the management of hypogonadism, no specific guideline and recom-
mendation have ever been published to care for patients with KS 
in various developmental stages. The aim of the present study is 
summarize available evidence on KS providing a list of suggestions 
and recommendations on behalf of European Academy of Andrology 
(EAA) and endorsed by the European Society of Endocrinology in 
order to correctly manage patients with KS from pre-natal period 
to adulthood.
2  | METHODOLOGY OF THE GUIDELINE 
COMPOSITION
2.1 | Data identification
The EAA guidelines committee commissioned an expert task force of 
academicians with clinical expertise in the field to create new guide-
lines for the management of KS. All experts involved are androlo-
gists with a various background (urology, genetics, paediatrics and 
endocrinology). PubMed was searched for articles in English with 
the search term ‘Klinefelter’ (the search period involved all literature 
regarding KS starting from 1942 to June 2020). The text was drafted 
in a group effort following scrutiny and discussion of the best evi-
dence from published literature. Thus, a series of consensus recom-
mendations and suggestions according to the GRADE (Grading of 
Recommendations, Assessment, Development and Evaluation) sys-
tem was generated.1
2.2 | Levels of evidence and grades of 
recommendation
The GRADE system is a method of developing evidence-based 
guidelines, involving key recommendations and the use of a consist-
ent language and graphical descriptions for standardizing the grad-
ing of both the strength of recommendation and the quality of the 
evidence.1 widely used from scientific societies including the EAA. 
According to GRADE, the task force used the following internation-
ally shared coding system: [1] ‘we recommend’ indicates a strong 
recommendation; [2] ‘we suggest’ denotes a weak recommendation. 
As far as the evidence grading is concerned: ⊕◯◯◯ denotes ‘very 
low-quality evidence’; ⊕⊕◯◯ ‘low quality’, ⊕⊕⊕◯ ‘moderate 
quality’ and ⊕⊕⊕⊕ ‘high quality’.
Largely, a ‘⊕⊕⊕⊕’ score is awarded to evidence that is based 
on randomized controlled trials (RCTs) and meta-analyses, and a 
‘⊕⊕◯◯’ score to evidence that is based on observational studies. 
Specific methodological characteristics (quality, consistency, direct-
ness and effect size) increase or decrease this score.
Statements on AETIOLOGY AND PREVALENCE.
 I Klinefelter syndrome (KS) is the most frequent sex chromosomal 
anomaly in males, described by a karyotype with one or more 
extra X Chromosome (most frequently 47,XXY) in men.
 II KS is associated with testicular malfunction resulting very often 
in hypogonadism and/or infertility
 III The classical description of the adult male with KS includes 
primary testicular failure with small testes (1-5 mL), hypergo-
nadotropic hypogonadism, gynaecomastia, infertility (mostly 
in KS. Moreover, compared to the general male population, a higher prevalence of 
dental, coagulation and autoimmune disorders is likely to exist in patients with KS. 
Both genetic and epigenetic effects due to the supernumerary X chromosome as well 
as testosterone deficiency contribute to this pathological pattern. The majority of pa-
tients with KS is diagnosed during adulthood, but symptoms can already become ob-
vious during infancy, childhood or adolescence. The paediatric and juvenile patients 
with KS require specific attention regarding their development and fertility.
Conclusion: These guidelines provide recommendations and suggestions to care for 
patients with KS in various developmental stages ranging from childhood and ado-
lescence to adulthood. This advice is based on recent research data and respective 
evaluations as well as validations performed by a group of experts.
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azoospermia), sparse body hair, extended body length in re-
lation to parentally derived target height, an increased risk 
for osteoporosis, metabolic syndrome and psychosocial 
disturbances
 IV Except for small testes, no consistent clinical features or specific 
abnormalities irrespective of age have been identified
 V The phenotypic spectrum is extremely wide, and the main clini-
cal features are not present in infancy and childhood and may not 
become evident until after the onset of puberty
 VI The cohort of men with KS exhibits an increased morbidity and 
mortality compared to the general male population
2.3 | Aetiology
The supernumerary X of KS originates in 50% from paternal non-
disjunction of sex chromosomes during meiosis I. The remaining 
50% originate from maternal nondisjunction during meiosis I or 
II, or during early post-zygotic mitotic divisions.2,3 An associa-
tion of the frequency of KS with increasing maternal age can be 
attributed to maternal meiosis I errors. An association of pater-
nally derived 47,XXY with the father’s age has been described, 
as well.4
Gene-dosage effects, of which SHOX related to the tall stature 
in KS is a leading example,5 in combination with escapee genes from 
X chromosomal inactivation, are most likely co- factors constituting 
the phenotype.4,6,7
In addition, the androgen receptor (AR) gene, located in Xq11.2–
q12, is of interest concerning genotype/phenotype correlations. The 
AR gene contains a highly polymorphic trinucleotide repeat (CAG)
n in exon 1, which is correlated with physiological androgen effects 
and might be associated with androgen-dependent features of KS 
6,8,9. FSH polymorphisms might affect serum FSH in men with KS,10 
as well as other genetic features of the X chromosome might con-
tribute to phenotype variations.11
2.4 | Prevalence
The prevalence of KS is 1–2/1000 according to studies involving sys-
tematic screening of male newborns in the 1960-1970s.12-14
Subclasses of KS are the classic 47,XXY form, which repre-
sent approximately 80-90% of the cases, higher-grade aneu-
ploidies (48,XXXY, 49,XXXXY or 48,XXYY), mosaicisms (mainly 
47,XXY/46,XY) and structurally abnormal X chromosomes (eg 
47,iXq,Y)15,16 that overall account for the remaining 10-20% of 
cases.
However, the prevalence of a 47,XXY karyotype among male blas-
tocysts examined during pre- implantation genetic testing (PGT) has 
been reported as 0.9% (17/1794), with a significant correlation with 
maternal age. This discrepancy might suggest that 47,XXY blastocysts 
result in a lower implantation rate and/or higher early miscarriage 
rate than euploid embryos or that infertile patients of advanced ma-
ternal age and referred to IVF/PGT produce a higher rate of 47,XXY 
blastocysts.17
2.5 | Low diagnostic rate
The typical clinical phenotype of men with KS, as described in the ear-
lier literature, is present in a minority of patients (Figure 1). Phenotypic 
variability, and especially a presentation with mild clinical features, often 
leads to diagnostic delay or non-diagnosis.8,15,18 It has been estimated 
that 50-75% of males with KS never obtain a diagnosis.19,20 To increase 
the diagnosis rate, screening all male newborns has been suggested.21 
This, for example, can be facilitated by the detection of an increased 
gene copy number in DNA from dried blood spot samples.22 In general, 
efforts that improve our ability to reach an early diagnosis should be 
encouraged. Moreover, since the great majority of men with KS are di-
agnosed during infertility evaluation and pre-pubertal clinical signs are 
not specific for KS, diagnosis during childhood and adolescence is quite 
rare, representing about 10% of all the diagnoses.19 Indeed, the advan-
tages of a correct diagnosis and early diagnosis are evident for better 
management and prevention of diseases related to KS.15,21
3  | CLINIC AL PIC TURES,  DIAGNOSTIC 
STEPS AND THER APY
3.1 | Genetics
3.1.1 | Recommendations
1. We recommend that a pre-natal diagnosis of KS is confirmed 
on a chromosome analysis on peripheral blood postnatally (1, 
⊕⊕⊕◯).
2. We recommend conventional karyotyping on peripheral blood 
cells for diagnosis of KS (1, ⊕⊕⊕◯).
3. We recommend that patients with KS and/or their parents are 
offered genetic counselling; pre-natal counselling should be non-
directive (1, ⊕⊕⊕◯).
4. We recommend karyotype analysis for detecting KS in men with 
non-obstructive azoospermia or (severe) oligozoospermia (total 
sperm count < 10 x 106/ejaculate or sperm concentration < 5 x 
106/ml (1,⊕⊕⊕ ◯).
5. We recommend karyotype analysis for detecting KS in men with 
primary hypogonadism (low serum levels of testosterone) and 
elevated serum levels of gonadotropins (LH and FSH) combined 
with small testicular volumes (<5 ml per testis) (1, ⊕⊕⊕◯).
3.1.2 | Evidence
Diagnosis of KS depends on determination of the karyotype.2,3,8 
The prevalence of KS rises up to 3-4% among infertile males, to 6% 
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among men with a total sperm count < 10 million/ejaculate and to 
10-15% in non-obstructive azoospermic subjects.23,24 The majority 
of men with KS are azoospermic and only 10% approximately pre-
sent with severe oligozoospermia or cryptozoospermia, whereas the 
prevalence in men with normozoospermia is virtually zero.2,3,8 Low 
testosterone levels are described in about 50% of adults with KS,2,18 
but nearly all patients have elevated LH levels which reflects the 
primary testicular (Leydig cell) damage in these patients. Therefore, 
overt or subclinical hypogonadism is almost a hallmark of KS25 and 
clinical signs of hypogonadism are present in most men. However, 
the real prevalence of KS among men with primary or subclinical hy-
pogonadism is not known.
3.1.3 | Values and remarks
Determination of karyotype in patients with suspicion of KS or the 
exclusion thereof determines the pathway of counselling, further 
diagnostics and treatment. We place a high value on the recommen-
dation on conventional karyotyping as the choice for confirming a 
clinical suspicion of KS.
Karyotyping should be considered in cases of low testicular 
volume (<5 ml) which may also be present without overt primary 
hypogonadism, apart from non-obstructive azoospermia or severe 
oligozoospermia (which must be confirmed in more than one semen 
analysis). Other possible causes of non-obstructive azoospermia or 
severe oligospermia must be considered. Especially cases with cen-
tral hypogonadism might present with small testes, non-obstructive 
azoospermia or severe oligozoospermia and not all of them are can-
didates for karyotype analysis.
KS may be diagnosed pre-natally by cytogenetic evaluation [con-
ventional karyotyping or array-CGH (array-comparative genomic 
hybridization)] of chorion villus tissue or amniotic fluid. Massively 
parallel sequencing of circulating cell-free foetal DNA in maternal 
plasma has allowed for the development of non-invasive pre-natal 
testing (NIPT). Currently, NIPT is widely used for the screening for 
autosomal trisomies, such as trisomy 13, 18 and 21. However, data 
on sensitivity and specificity of the detection of sex chromosome 
aneuploidies (SCA) is sparse and there is a tendency towards in-
creased false-positive results. Importantly, NIPT is not a diagnostic 
test and requires cytogenetic confirmation.26
In cases of pre-natal diagnosis of KS, genetic counselling is strongly 
advised and in some countries even mandatory according to law. Such 
counselling is non-directive and will inform the parents about the pu-
tative risks for patients with KS, up-to-date treatment options and ex-
periences of clinicians treating children, adolescents and adults with 
F I G U R E  1   Signs and symptoms of Klinefelter syndrome (KS) at various stages in life. It is indicated that these symptoms may be seen 
in some or many patients with KS, depending on their age. Most of these symptoms are not inherent to KS and are, therefore, not specific. 
Small firm testes can, however, be considered quite specific. Also, the combination of symptoms in adults can be considered specific and 
promote the diagnosis of KS
Signs:
None




• Long legs and tall stature
• Increased fat/lean mass 
proportion
• Speech and learning 
difficulties
• Behavioural, social and 
psychological difficulties
• Puberty starts, then arrests
• Reduced testicular growth, firm testes
• Long legs and tall stature





• Signs of hypogonadism
• Behavioural, social and psychological 
difficulties
• Infertility (azoospermia, severe oligozoospermia)
• Testicular hypotrophy (< 5 ml)
• Hypergonadotropic hypogonadism/compensated 
hypogonadism
• Signs of hypogonadism
• Gynecomastia
• Osteopenia/osteoporosis
• Obesity, increased fat/lean mass proportion
• Metabolic and CVD risk
• Psychosexual and social problems
• Neoplasia (breast, haematological diseases, 
extragonadal germ cell tumours, Leydig cell tumours)
• Autoimmune disorders
• Ophthalmologic problems (retinal dysfunction, 
impaired day vision/night vision)
• Dental problems (taurodontism, caries)















Non-specific except for small firm testes
Signs:
Many
Non-specific except for small firm testes, but
specific in their combination
Late diagnosis
Clinically silent Clinically evident Full syndrome
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KS. Contact to KS patient and parent groups may be provided. Any de-
cision of the parents regarding the child must be absolutely individual.
Additional screening for mosaicism on higher number of meta-
phases, potentially using fibroblasts or array-CGH, is suggested if 
the clinical suspicion is strong and the result of the chromosome 
analysis is normal. However, the more expensive analyses such as 
array-CGH are not recommended for routine use.
Determination of the length of the CAG repeat polymorphism of 
the AR gene (a parameter inversely related to androgen sensitivity) 
might be useful in decision-making regarding androgen replacement in 
cases of patients exhibiting features of hypogonadism and low-normal 
serum testosterone concentrations.6,9 Diagnostic procedures related 
to hypermethylation and differential gene expression remain experi-
mental and do not have direct clinical consequences at this time.
3.2 | Developmental issues in infants and pre-
pubertal children
3.2.1 | Testicular development and function of the 
hypothalamic-pituitary-testicular axis
Recommendations
6. We suggest karyotype analysis for detecting KS in boys born 
with cryptorchidism, especially the bilateral forms, who do not 
experience spontaneous descent of the testes at the first year 
(2, ⊕⊕◯◯).
7. We recommend treating cryptorchidism in children with KS ac-
cording to the current treatment guidelines in children without KS 
(1, ⊕⊕⊕◯).
8. We recommend general physical examinations in pre-pubertal 
children with KS including a testicular evaluation. These should 
be performed biennially or as deemed as appropriate. Suspected 
neurological or psychiatric deficits should be examined by respec-
tive specialists (1,⊕⊕⊕ ◯).
9. We suggest determination of LH and testosterone during the first 
2-3 months after birth in children with pre-natal diagnosis of KS 
when it might have a therapeutic consequence (ie diagnosis of 
micro-penis) (2,⊕◯◯◯).
10. We recommend against cryopreservation of testicular tissue or 
spermatogonial stem cells retrieved from pre-pubertal children 
with KS (1,⊕⊕⊕◯).
11. We recommend against testosterone supplementation during 
early childhood in all patients with KS except in cases of micro-
penis (1,⊕⊕⊕◯).
Evidence
In KS, testicular degeneration and abnormal testicular function may 
start during the foetal period of life and worsen with age, but no reli-
able data exist on ultrasound imaging of the testes in children with 
KS.27-31 Some boys with KS show clinical signs of intrauterine hypo-
gonadism such as cryptorchidism, reduced penile length and testicu-
lar volume.32-35 Boys with KS rarely fulfil the criteria for micro-penis 
(<−2.5 SD), although, one study found a prevalence of 17%.35 In 
otherwise healthy patients with testicular failure and micro-penis, 
testosterone therapy in infancy is widely accepted.36-38
Patients with cryptorchidism may have a prevalence of 3 - 4% of 
chromosomal anomalies, especially frequent in the bilateral form of 
cryptorchidism.39 Among chromosomal anomalies detected in crypt-
orchid boys, KS represents the most frequent alteration. A study on 
600 newborns with isolated cryptorchidism found a prevalence of 
KS of 1.3% that increased to 2.6% when considering only boys who 
were still cryptorchid at 12-24 months.39 The prevalence of KS was 
even higher in persistent bilateral forms of cryptorchidism (4.2%) 
than in unilateral forms (1.6%).39 However, the exact prevalence 
of cryptorchidism at birth in patients with KS is unclear, and few 
studies examined this aspect. The largest studies reported that 27-
37% of patients with KS had a history of undescended testes 2,40,41. 
Orchidopexy before the age of twelve months is recommended as 
for non-KS cryptorchid boys.36,42 Treated cryptorchidism does not 
reduce the chances for positive sperm retrieval in patients with KS.43
Conflicting data regarding the surge in testosterone during the 
first 3 months after birth (mini-puberty) have been published. Some 
studies demonstrated low testicular testosterone levels in infants 
with KS.44,45 Another study reported testosterone concentrations 
within the normal range but significantly lower than controls.46 A 
recent investigation showed that during mini-puberty of infants with 
KS, serum levels of FSH and LH were significantly higher than in con-
trols (p < 0.05), as were Inhibin B and T (respectively p < 0.0001 and 
p < 0.005). No significant differences were found in height, weight, 
testicular volume and penile length.47
General pre-pubertal concentrations of testosterone, estra-
diol, FSH and LH are normal.48-57 However, some studies have 
shown that boys with KS may already be androgen deficient before 
puberty.34,35,58
Values and remarks
Preservation of testicular functions, especially sperm production, is 
closely linked to descended testes. As these testicular functions are 
impaired in KS anyway, these patients require high attention to man-
agement of undescended testes as early as possible (Table 1).
Testicular ultrasound may help to assess testicular development, 
but testicular palpation may also yield the required information. We 
recommend against testicular tissue cryopreservation and against 
spermatogonial stem cell retrieval in children with KS. So far, these 
procedures are not justified as there is no method of in vitro sper-
matogenesis, but this may change in future.59
We place a moderate value on the recommendation regarding 
determination of LH and FSH during the first three months after 
birth because treatment of hypogonadism in this period of life is cur-
rently not recommended. We place a high value to the recommen-
dation against testosterone supplementation during early childhood 
in all patients with KS, as it has currently no justification. However, 
in cases of micro-penis, serum hormone assessment could provide a 
justification for short term low-dosed systemic testosterone treat-
ment or local application of dihydrotestosterone (38; Table 1).
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The postnatal surge of sex hormones during the so-called mini-pu-
berty represents a diagnostic window for evaluating the hypotha-
lamic-pituitary-testicular axis in infancy and recognize poor testicular 
function and hypogonadism.60 The result of poor testicular hormonal 
function may be cryptorchidism.61 Endocrine evaluation of the testic-
ular function before puberty is challenged by very low concentrations 
of testosterone and low sensitivity of the generally available hor-




12. We suggest measurement of height according to centiles 
or standard deviation scores (SDS) as well as body pro-
portions and determinations of bone age in pre-pubertal 
children with KS depending on individual growth patterns 
(2,⊕⊕◯◯).
Evidence
During early infancy, growth of the KS boys is usually within the 
normal range. By the age of 5-6 years, growth velocity might be ac-
celerated resulting in significantly taller stature than expected on 
the basis of parental target height.5,32,63-67 In addition, significantly 
increased leg length already before puberty has been reported by 
several authors.63-65,67-69
Values and remarks
Growth should be monitored assessing height and body proportions in 
boys with Klinefelter syndrome, whenever possible according to cen-
tiles or SDS for the reference ethnic group of the patient and bone age 
should be determined in selected cases. However, the only parameters 
which would justify an intervention by testosterone supplementation 
are excessive growth compared to the estimated parental-derived tar-
get height or abnormal body proportions.5,64,65 In these cases, determi-
nation of bone age is important (Table 1). The side-effects on physical 
and psychological parameters can be rather significant and this form 
of therapy is rarely used nowadays. Since high dose T treatment is re-
quired to stop over-tall growth, and effects on testicular functions are 
unknown, such a procedure is generally seen with reluctance.
3.2.3 | Bone mineralization
Recommendations
13. We suggest determination of vitamin D blood levels and ade-
quate vitamin D and calcium supplementation in pre-pubertal 
children with KS (2,⊕◯◯◯).
14.  We suggest assessment of bone mineral status during childhood 
in case of vitamin D deficiency biennially in patients with KS 
TA B L E  1   Summary of the most important parameters to be tested and/or related to therapeutical approaches from childhood to 
adolescence in patients with KS
Parameter to be tested and/or treated Infancy and childhood Puberty and adolescence
Cryptorchidism Treated according to the current guidelines –
Physical examination including testis and 
mammary gland evaluation
Biennially or as deemed as appropriate
Testicular ultrasound if required
Annually or as deemed as appropriate
Testicular ultrasound in all patients
Cognitive evaluation and or specialist 
consultation
Monitor speech development, learning abilities 
psychosocial problems.
Support, if necessary
Monitor educational problems, social 
training and psychological problems
Support, if necessary
Growth, body proportion and weight Evaluated according to SD or centiles: pay attention to 
body proportions and overweigh or obesity
Evaluated according to SD or centiles: 
pay attention to body proportions 
and overweigh or obesity
Fertility issues
Information
Semen collection and cryopreservation
Testicular biopsy and cryopreservation
Inform parents
–
Inform patients and their parents if 
deemed adequate
Selected cases after careful 
information
Selected cases in azoospermia
Assessment of vitamin D and calcium In all patients
Support, if necessary
Bone mineral status in case of vitamin D deficiency
In all patients
Support, if necessary
Bone mineral status in case of vitamin D 
deficiency
Assessment of LH and testosterone Only in the presence of micro-penis In all patients
Testosterone therapy Selected cases with micropenis In the presence of hypogonadism
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(DXA scan, size-corrected determinations using a three-step-
method are required) (2,⊕◯◯◯).
Evidence
Normal lumbar bone mineral density (BMD), and whole body bone min-
eral content (BMC) as evaluated by whole body DXA scan in KS boys 
and adolescents (4.3 - 18.6 years of age) has been reported, indicating 
that the risk of osteopenia/osteoporosis may not be present until after 
puberty.70 It was found in a group of 7/40 KS boys (11.96 ± 3.97 years 
of age) that z-scores ≤−2.0 as evaluated by phalangeal amplitude-de-
pendent speed of sound were present as well as higher parathyroid 
hormone levels and a significant reduction of 25-hydroxyvitamin D 
concentrations. This study is rather small and needs confirmation.71
Values and Remarks
Studies evaluating the bone status and metabolism of children and 
adolescents with KS are very rare and not uniform. We place a mod-
erate value on the recommendation to check vitamin D levels and, 
if needed, supplement with vitamin D preparations and calcium to 
maintain healthy bones. We put a moderate value on the recommen-
dation to assessment of bone mineral status because it is important 
to diagnose and treat osteopenia/osteoporosis as soon as possible to 
allow achievement of peak bone mass, but probably only less than 




15. We recommend measurement of weight using centiles or 
standard deviation scores in pre- pubertal children with KS 
(1,⊕⊕⊕◯).
16. We recommend against testosterone treatment in infants and 
pre-pubertal boys with KS (1,⊕⊕⊕◯).
Evidence
Findings of an unfavourable body composition already present in 
childhood and early adolescence with elevated body fat mass de-
spite normal body mass index and normal lean body mass for age 
as determined by DXA70 or triceps/subscapular skinfolds32,40,66,72 
point out causes other than low testosterone. Genetic causes (over-
expression of X-linked genes, skewed X chromosome inactivation or 
a longer-than-normal CAG repeat polymorphism in the AR gene) and 
psychosocial aetiologies are both plausible: studies addressing these 
possible relations have to be further validated.4,6,73-76
Testosterone supplementation in early childhood was pro-
posed, particularly in the USA.77-79 An improved neurodevelop-
mental outcome in boys with KS treated with testosterone during 
infancy compared to non-treated boys with KS was claimed, but 
the treatment was not randomized or blinded.77,78 Two random-
ized trials have been conducted in children with KS. The effect on 
body composition in 20 infants aged 6 to 15 weeks who were ran-
domized to testosterone injections or no treatment was also eval-
uated. A normal fat mass in treated boys compared to untreated 
boys was seen, the latter presenting with a significant accumu-
lation of fat tissue as compared to 46,XY-controls.79 In addition, 
a double-blind, randomized, placebo-controlled study evaluated 
treatment with low-dose synthetic oral androgen (oxandrolone) in 
pre-pubertal boys aged 4 to 12 years.80-82 The authors reported 
improvements in areas of visual-motor performance, anxiety/
depression and social functioning, but no effect on cognition or 
attention.82 Furthermore, a significant reduction in body fat, tri-
glycerides and high-density lipoprotein was found.80 Importantly, 
the oxandrolone treated boys had an increased risk of early go-
nadarche and pubarche, as well as advanced bone age, although 
no significant differences in T and gonadotropin concentrations 
between treated and untreated boys were found.81
Values and Remarks
We place a high value on the recommendation to assess weight and 
possibly fat/lean proportions as well as keeping them within normal 
range as they are important for subsequent metabolic equilibrium 
(Table 1). To this end, also waist circumference and, where available, 
triceps/subscapular skinfolds can be assessed in pre-pubertal chil-
dren with KS on an individual basis.
Further randomized controlled trials are required to confirm pos-
sible positive short- and long-term effects of testosterone treatment 
in infants and pre-pubertal boys with KS (Mason et al. 2020). Current 
knowledge does not support such a treatment.
3.2.5 | Psychological aspects
Recommendations
17.  We recommend speech therapist control and therapy, mon-
itoring learning disabilities, social training and psychological 
support, in pre-pubertal children with KS if needed (1,⊕⊕⊕◯).
Evidence
Boys with KS are known to have an increased risk for psychosocial 
and educational problems.66,83 General intelligence in KS is pre-
served variably and verbal abilities might be decreased. KS can, al-
beit not mandatorily, present with lower general cognitive abilities, 
reduced knowledge achievements as well as some attenuated as-
pects of attention and executive functions.83-92 In patients with KS, 
the cognitive phenotype is often described by impaired performance 
on measures of language development, visuospatial and academic 
abilities. In younger boys with KS, a delay in speech development 
may be observed, whereas significant deficits in higher aspects of 
expressive language are more common in adolescents. In addition, 
it has been shown that KS is associated with difficulties in identify-
ing and verbalizing emotions. Furthermore, patients with KS may be 
more easily emotionally aroused.93-98 There are also reports about 
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an increased distractibility and an increased risk for hyperactivity 
and attention problems in patients with KS.90,99-101
Values and remarks
We place a high value to the recommendations to monitor speech 
development, learning abilities as well as psychosocial problems 
and give support, if necessary (Table 1). There are suggestions 
that early testosterone treatment may improve psychological 
development in patients with KS.66,77,78,102 However, data are 
lacking quality to recommend this procedure to all children with 
KS.103 So far, scientific evidence is not sufficient to support this 
procedure.




18. We recommend that information on fertility issues is given 
to adolescent patients with KS and, if deemed adequate, his 
parents (Good Clinical Practice statement).
19. We suggest testicular ultrasound evaluation during puberty of 
patients with KS and regularly at follow-up visits (2, ⊕◯◯◯).
20. We suggest semen collection in adolescents with KS after careful 
information and assessment of the wish of the patient and cryo-
preservation if motile spermatozoa are present (2, ⊕⊕◯◯).
21. We suggest that adolescents with KS might undergo a testicular 
biopsy for testicular sperm extraction (TESE) either using mul-
tifocal (standard TESE) or microdissection-TESE (mTESE) and 
consequent sperm cryopreservation in selected cases requiring 
specific counselling, provided their physical and mental maturity 
is apt for this decision (2,⊕⊕◯◯).
Evidence
At the beginning of puberty, which in general occurs at a normal 
age, testes grow to a minor extent and subsequently shrink. In 
parallel with this, gonadotropin levels rise to the greatly elevated 
serum concentrations as seen in adults with KS. The degeneration 
of germ and Sertoli cells accelerates during puberty, and moreo-
ver, extensive fibrosis and hyalinization of the seminiferous tu-
bules occur, as well as hyperplasia of Leydig cells and fibrosis of 
the interstitium.27-30 Spermatogenesis cannot be observed in the 
majority of seminiferous tubules. However, a few tubules with 
ongoing spermatogenesis and few spermatozoa can be found. In 
adolescents aged 13-14 years, spermatozoa were collected in only 
10% of the TESE attempts, while in adolescents of 15-19 years, 
spermatozoa were found in 45%.104 Sperm retrieval rates by TESE 
in adolescents with KS aged 15-19 years are comparable with 
those reported in young adults who are 20-30 years old.105-107 It 
was also found that adolescents with LH ≤ 17.5 IU/l, along with 
testosterone levels ≥ 7.5 nmol/l had the best success rate (54%), 
which fell to 44% with higher serum LH levels, whereas those 
with low serum testosterone concentrations (<7.5 nmol/l), had no 
sperm retrieval, irrespective of LH.106 See Figure 2a-c for an exam-
ple of testicular tissue in KS.
Values and remarks
We place a high value to the recommendation to provide the in-
formation on fertility status and treatment possibilities to the 
patients with KS and their parents. It is important that further 
medical treatment is undertaken within a setting of empower-
ment of the patient and his family. We place a lower value to the 
suggestion regarding semen collection and TESE in adolescents, 
because not all pubertal patients are psychologically ready to 
focus on fertility and because success rates are similar if these 
procedures are performed later. Adolescents might undergo 
a surgical procedure to attempt a TESE, provided they exhibit 
F I G U R E  2   (a) Testicular histology in an adult patient with Klinefelter syndrome. The biopsy is dominated by Sertoli- cell-only tubules, 
Leydig cell hyperplasia with one large Leydig cell nodule (*) and completely hyalinized ‘ghost’ tubules (white dotted circles). Note two 
types of Sertoli cell-only seminiferous tubules; type A which contain differentiated Sertoli cells (A), and type B which contain incompletely 
differentiated Sertoli cells (B). Periodic acid-Schiff staining. The bar denotes 100 µ. Courtesy of Lise Aksglaede.(b + c) Testicular histology 
(right testis) of a young adult/adolescent patient (age 18 years) with non-mosaic 47,XXY Klinefelter syndrome. b: section with various 
types of tubules, containing elongated spermatids but also a ‘ghost’ tubule c: section with almost intact tubules, containing more 
elongated spermatids. PAS-staining. The bar denotes 100µ. Further patient data: testis volume right: 2.5 ml. LH 6.3 IU/L, FSH 29 IU/L, 
total testosterone 7.5 nmol/L, Inh B 15.4 pg/mL (normal value: >100 pg/mL), as the lower limit of detection is 10 pg/mL, this finding might 
indicate remnant processes of spermatogenesis. AMH 2.6 ng/mL (normal range for age 18 y: 1.3-4.8 ng/mL). Courtesy of Sabine Kliesch. 
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physical and mental maturity and the decision to preserve their 
fertility is clearly not made by the parents but the patient him-
self. We put also a moderate value to the recommendation to 
perform testicular ultrasound every year, because it may help 
to assess testicular development. Not all pubertal patients are 
mature enough to talk about their fertility. However, all patients 
with KS should be fully informed on their fertility status and pos-
sibilities of fertility preservation.108 Information should be pro-
vided at a level appropriate to the patient’s age and cognitive 
level (table 1).
3.3.2 | Function of the hypothalamic-pituitary-
testicular axis
Recommendations
22. We recommend assessment of Tanner stages, pubertal de-
velopment, measurement of testosterone and gonadotropins, 
signs and symptoms of hypogonadism, height, weight, waist 
circumference and body proportions starting prior to the pre-
dicted start of puberty in patients with KS and at individually 
determined intervals thereafter (the time-window for the start 
of puberty does not differ from boys with a karyotype of 
46,XY) (1,⊕⊕⊕◯).
23. We recommend testosterone supplementation in case of delayed 
puberty and/or symptoms of hypogonadism associated with 
low-normal testosterone and supra-normal LH serum concen-
trations (LH> 2 SD according to age-related references), after 
the fertility issues have been addressed (see above) (1,⊕⊕⊕◯).
24. We suggest against testosterone therapy in adolescents with KS 
and with compensated hypergonadotropic hypogonadism (2, 
⊕⊕⊕◯).
Evidence
From around mid-puberty, testosterone and INSL3 concentrations 
stop to increase and remain in the low-normal range in most patients 
with KS.48,49,51,109,110 Concomitantly, FSH and LH concentrations 
increase to hypergonadotropic levels.48,49,51,109,111 Inhibin B con-
centrations increase, but not as much as expected during puberty, 
and decline markedly within a year of pubertal onset and remain 
undetectable from the end of puberty onwards in the vast major-
ity of patients with KS.28,50,111 The physiological pubertal decline in 
serum AMH occurs later in boys with KS than observed in healthy 
boys.53,55,112 Oestradiol levels have been reported to be normal113 
or high.114
A central issue is the normative age-related secretion of LH. Data 
are scarce and might be specific to local laboratories. There are some 
publications reporting such age-related values.56,115
A hypergonadotropic state with compensated hypogonadism is 
found in over 60% of KS cases allowing for spontaneous accomplish-
ment of pubertal development.104 However, about 25% of patients 
with KS have testosterone below normal levels and in some cases 
the diagnosis is made because of prolonged progression of pubertal 
development, which should not be confused with a delayed onset of 
puberty.111
Values
We place a high value on the recommendation for peripubertal 
examinations. These should be based on an individual prediction 
of pubertal onset, which is derived from the parents’ pubertal 
history. Assessment of the fertility status should ideally be per-
formed before the start of testosterone substitution. We place a 
high value on the recommendation to treat patients with KS and 
low testosterone levels as well as accompanying symptoms of an-
drogen deficiency with an adequately dosed testosterone replace-
ment (Table 1).
Remarks
There are only a small number of studies on testosterone supplemen-
tation in patients with KS during puberty, and no controlled trials. 
However, such a regimen may ensure, as in other adolescents with 
hypogonadism, normal completion of puberty as well as improved 
physical and psychological development, educational achievements 
and social integration.116-122
Randomized controlled trials are needed to elucidate the influ-
ence of testosterone replacement therapy on pubertal development 
and spermatogenesis in patients with KS. There are also no random-
ized controlled trials evaluating the possible deleterious impact of 
testosterone treatment on successful sperm retrieval or its possible 
effects on reproductive outcomes in men with KS. Testosterone 
preparations may theoretically suppress any remaining spermato-
genesis if the endogenous LH drive is reduced. Therefore, it is better 
to assess the fertility status before this treatment. However, indi-
vidual decisions should be made. The use of hCG or anti-oestrogens 
(aromatase inhibitors or selective oestrogen receptor modulators) 
on compassionate care grounds may have a positive effect on go-
nadotropin secretion even in the hypergonadotropic state as seen in 
KS. Theoretically, this may result in higher levels of intra-testicular 
as well as serum testosterone and maintained (or even augmented) 
spermatogenesis. However, no controlled trials are available and ev-
idence is poor. Hence, such therapies cannot be recommended in 
general.
No data have been published on the possible positive or nega-
tive effects of testosterone treatment in boys with KS and compen-
sated hypergonadotropic hypogonadism. It is suggested that in the 
absence of clinical signs and symptoms of hypogonadism these boys 
should not be treated with testosterone.
3.3.3 | Cognitive and psychological aspects
Recommendations
25. We recommend speech therapist control, monitoring educa-
tional problems, social training and psychological support in 
adolescents with KS, if needed (1,⊕⊕⊕◯).
154  |     ZITZMANN eT Al.
Evidence
As younger children with KS, pubertal boys might have educational 
and psychosocial problems. Boys with KS might show deficits in verbal 
memory, verbal fluency, word retrieval, expressive/receptive vocabu-
lary difficulties, as well as planning, organization and decision-making 
problems.90,91,123-126 Although all of these have been related to lower 
school/academic performance, patients with KS are not generally 
learning disabled. Limitations in communication might affect social ad-
aptation and behavioural aspects, as well as the development of per-
sonality, which may result in social and professional problems.6,126,127
Values and remarks
We place a high value to the recommendation to monitor speech de-
velopment, educational, social and psychosocial problems and give 
support, if necessary (Table 1). Notwithstanding, further studies are 
needed to evaluate the impact of educational and psychosocial prob-
lems of patients with KS on their final education, socio-economic 
status, psychological well-being and general quality of life in adult-
hood. Also see recommendation #16 against testosterone treatment 
during childhood in KS.
3.4 | Pathophysiology and clinics in adults
3.4.1 | Hypogonadism
Recommendations
26. We recommend initiation of testosterone substitution in pa-
tients with KS with hypogonadism as diagnosed according 
to established guidelines on hypogonadism, if possible once 
fertility issues have been addressed (1,⊕⊕⊕◯).
27.  We recommend that testosterone substitution in patients with 
KS should follow the established guidelines on hypogonadism 
using the usually suggested monitoring intervals for clinical as-
sessment, safety parameters (haematocrit, PSA) and dose titra-
tion (1,⊕⊕⊕◯).
28.  We recommend endocrine evaluation every 12 months in adult 
patients with KS who are not on testosterone substitution 
(1,⊕⊕◯◯).
Evidence
Most adults with KS have serum testosterone levels within the low-nor-
mal or sub-normal range, but some may have very low amounts of this 
steroid and others may even have normal levels. In adult patients with 
KS, not only levels of testosterone, but also insulin-like factor 3 (INSL3), 
and inhibin are decreased, whereas FSH and LH are highly elevated, 
while estradiol and SHBG are comparable to controls. Testosterone re-
placement therapy in adult men with KS should follow the established 
guidelines on diagnosis and treatment of hypogonadism.128
Values and remarks
Assessment of serum concentrations of sex steroids and gonado-
tropins is pivotal to understand the status of the patients with KS 
in terms of possible hypogonadism and fertility issues (table 2). It is 
paramount to monitor these values and safety parameters to tailor 
the hormone replacement therapy to establish the known benefits 
and avoid side-effects.2,8 Treatment of hypogonadism in KS should 
be started as soon as diagnosis is made. The effects of testosterone 
replacement might be modulated by the CAG repeat polymorphism 
within the AR gene.6
A recent meta-analysis including 21 observational and 22 inter-
ventional studies showed that non- treated patients with KS have 
worse metabolic profiles (fasting glycemia, HOMA index, HDL, LDL) 
and body composition (BMI, waist circumference) and reduced BMD 
with respect to controls. On the other hand, testosterone treatment 
in hypogonadal men with KS improved body composition and BMD 
at the spinal level. The effects on lipid and glucose profile were less 
significant evident.129 Larger and longer placebo-controlled RCT is 




29. We recommend semen analysis and sperm cryopreserva-
tion in all adult patients with KS and a wish for paternity 
(1,⊕⊕⊕◯).
30. We recommend that all patients with KS and confirmed azoo-
spermia as well as a current or putative future wish for paternity 
undergo a testicular biopsy for testicular sperm extraction (TESE) 
either using multifocal (standard TESE) or microdissection-TESE 
(mTESE) and consequent sperm cryopreservation (1,⊕⊕⊕◯).
31. We suggest against starting testosterone replacement therapy 
in patients with KS when a TESE is planned, due to the possible 
suppression of gonadotropins and further suppression of rem-
nant spermatogenesis (2,⊕⊕◯◯).
Evidence
Motile spermatozoa that can be cryopreserved from semen are 
found in approximately 10% of men with KS. In azoospermic men, 
focal spermatogenesis may be discovered with the possibility of sur-
gical extraction of viable spermatozoa. See Figure 2a-c for an ex-
ample of testicular tissue in KS. No differences in terms of sperm 
retrieval have been found between classic-TESE and micro-TESE.130 
Spermatozoa can be found in about 30-60% of patients with KS 
and the reported live birth rate by assisted reproduction is about 
16%. Although no direct comparison is available, the success rate 
of ICSI seems to be reduced in KS when compared to the general 
population.131
Values
We place high value on these recommendations because semen 
sampling is a non-invasive procedure and semen sampling should 
therefore be offered after puberty as soon as the patient can pro-
vide a sample (Table 2). Conventional TESE or micro-assisted TESE 
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(mTESE) in azoospermic patients with KS is the next step to obtain 
spermatozoa. These spermatozoa can be used later for methods of 
assisted reproduction (ICSI).
Remarks
As offspring seems not to be affected by the genetic condition of the 
father, it is unclear whether offering PGT or pre-natal genetic analy-
ses is required. Genetic counselling however is mandatory. In fact, it 
is the question whether 47,XXY spermatogonia are able to complete 
meiosis or, in contrast, some spermatogonia lose the supernumer-
ary X chromosome, hence becoming normal 46,XY cells and then 
proceed through meiosis.
It is still debated whether the chances to find foci within the 
testes with remnant intact spermatogenesis decrease with ad-
vancing age in KS.132-134 Fertility in KS may also be linked to their 
Leydig cell functionality.106 Nevertheless, in difference to adoles-
cents and younger men with KS (see above), no clinical, biochemi-
cal or hormonal parameter has been clearly associated with higher 
or lower chances of finding spermatozoa in adult men with KS. 
Similarly, it is unclear whether previous testosterone treatment 
decreases the success rate of TESE. Therefore, we cannot recom-
mend for or against stopping testosterone therapy prior to TESE, 
but suggest against starting testosterone treatment when a TESE 
is planned. Hypogonadal men not receiving testosterone therapy 
might be treated on compassionate care grounds with hCG or 
anti-oestrogens (aromatase inhibitors or selective oestrogen re-
ceptor modulators, see 4.3.2.). However, no controlled trials are 
available and evidence is poor. Hence, such approaches cannot be 
recommended in general.
3.4.3 | Metabolic disorders, body composition, 
cardiovascular risk and thrombosis
Recommendations
32. We recommend education on lifestyle and yearly assessment 
of weight, waist circumference, blood pressure, fasting glucose, 
HbA1c and lipid profile and adequate treatment in all patients 
with KS(1, ⊕⊕⊕◯).
33. We suggest thrombosis prophylaxis prior to long-term flights or 
exposure to other risks in patients with KS to attenuate the in-
creased risk for deep vein thrombosis and/or pulmonary embo-
lism (2, ⊕⊕⊕◯).
34. We suggest assessment of 12-lead ECG QTc time at least once in 
patients with KS (2,⊕◯◯◯).
Evidence
Men with KS suffer from higher rates in various diseases and 
a higher mortality, which results in a shortened lifespan (about 
2-3 years).8,41,135-140
Parameter to be tested Frequency
Physical examination 




Mammary gland ultrasound if required
Testis ultrasound on individual basis
Follow guidelines for gynecomastia
Cognitive evaluation 




Metabolic profile At least annually




Testosterone therapy only in the presence of hypogonadism (follow 
guidelines for hypogonadism)
Vitamin D and calcium 
determination




Semen collection and 
cryopreservation
Testicular biopsy and 
cryopreservation
Inform if not already notified if deemed adequate
In all patients desiring fertility
If fertility desidered in azoospermia
Thrombosis 
prophylaxis
Prior to long-term flights or exposure to other risks
12-lead ECG QTc time At the first visit and then on individual basis
DXA analysis at the 
lumbar and femoral 
levels and fracture 
risk assessment
At the first visit and then on individual basis
Treat if required (follow guidelines for osteoporosis)
TA B L E  2   Summary of the most 
important parameters to be tested and/
or related therapeutical approach in adult 
with KS
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KS is associated with increased fat mass and reduced lean 
mass, promoted by the intrinsic genetic background as well as 
hypogonadism. The resulting insulin resistance predisposes men 
with KS to a higher risk of developing type 2 diabetes melli-
tus.4,8,41,76,135,141 The conditions named above can explain, at least 
partially, the increased cardiovascular mortality and morbidity 
observed in patients with KS.8,41,135-140 These comorbidities are 
strongly related to hypogonadism (Corona et al. 2018). However, 
the latter cannot entirely explain the increased CV risk and other 
factors (such as epigenetic mechanisms and AR functionality) are 
most likely involved.4,6,9,142 Accordingly, testosterone replacement 
therapy does not completely attenuate the increased cardiomet-
abolic risk.129
There is some evidence that the cardiorrhythmic integrity of pa-
tients with KS is impaired, resulting in a reduced QTc time, which 
may eventually lead to sudden cardiac arrest. This impairment is 
most likely caused by gene over-dosage effects related to the addi-
tional X chromosome. As this pathology may result in a life-threat-
ening condition, we make suggestion No 33, although data are still 
based on smaller numbers of patients with KS 4,143.
A higher risk of thrombosis has been described in men with 
KS. The risk of deep vein thrombosis and pulmonary embolism is 
elevated in KS, with an overall three- to six-fold increased risk as 
compared to the general population.8,41,135-140,144 The risk may be 
attributed to higher levels of the procoagulatory substance PAI-1, 
which is associated with the genetic setting in KS as well as with 
lower testosterone levels.4 Testosterone treatment may reduce this 
risk, but evidence is still low.145,146
Value and remarks
We place a high value to the recommendations to give the pa-
tients correct information on lifestyle intervention (physical ac-
tivity, diet) to minimize cardiovascular risk factors, to monitor 
regularly cardiovascular risk factors, and treat obesity, diabetes 
and dyslipidaemia (Table 2). Maintaining eugonadal testoster-
one levels is most likely important to attenuate the chances of 
promoting a metabolic syndrome with advancing age in patients 
with KS, but evidence is still poor. Randomized controlled trials 
are needed to elucidate the role of testosterone substitution in 
patients with KS in the prevention of an unfavourable body com-
position, metabolic syndrome and type 2 diabetes mellitus. A re-
cent meta-analysis demonstrates that testosterone substitution 
ameliorates body composition, but not other cardiovascular risk 
factor.129 However, this conclusion is drawn mainly from obser-
vational studies (also see 4.4.1).
3.4.4 | Bone disorders
Recommendations
35. We recommend following the EAA clinical guidelines on man-
agement of bone health in the andrological outpatient clinic, 
bearing in mind that patients with KS are at risk of low bone 
mineral density (BMD) and fractures independently of their 
serum levels of testosterone (1, ⊕⊕⊕◯).
36. We recommend DXA analysis at the lumbar and femoral levels 
and fracture risk assessment at the first visit of adult patients 
with KS and then on an individual basis (1, ⊕⊕◯◯).
37. We suggest determination of vitamin D plasma levels in all adult 
patients with KS at the first visit and then on an individual basis, 
independently from their BMD, and proper vitamin D and cal-
cium supplementation when needed (2, ⊕⊕◯◯).
Evidence
Bone density is likely to be reduced in hypogonadism in general, as 
outlined in the respective EAA guideline147 and low bone mass and 
osteopenia/osteoporosis with a subsequent higher risk of fractures 
are present in up to 40% of patients with KS.122,148-150 However, no 
clear relation between serum levels of testosterone and BMD has 
been found in patients with KS and osteopenia/osteoporosis might 
also be present when testosterone concentrations are within the 
normal range.75 The decrease in bone mass is due to both reduced 
bone formation and higher bone resorption,148 and might be linked 
to a lack of peak bone mass at the end of puberty.
The higher fracture risk is linked also to other factors than hypo-
gonadism and low bone mineral density (BMD) (hypovitaminosis D, 
unfavourable ratio of fat mass/lean mass, associated comorbidities, 
low INSL3, X inactivation, AR sensitivity),6,148,149,151 as evidenced 
also by studies analysing bone formation and bone resorption serum 
markers such as osteocalcin152 and sclerostin.153 Patients with KS 
are likely to improve bone density upon testosterone replacement 
therapy,151 similar to observations in other patients with primary 
hypogonadism.129
Correction of vitamin D deficiency is also fundamental to main-
tain BMD.150. Calcitriol is the double-hydroxylated-form of Vitamin 
D3 (1,25-dihydroxy-cholecalciferol) that does not require hydroxyl-
ation at the hepatic and renal level. The direct substitution may be 
beneficial in cases of some chronic diseases, but requires close mon-
itoring of calcium levels in the blood while during substitution with 
cholecalciferol, the synthesis of the required amount is regulated by 
the system itself. Nevertheless, also substitution with cholecalcif-
erol requires control of serum levels of Vitamin D.154,155
Values and Remarks
Young KS subjects may have normal BMD in childhood and at the be-
ginning of pubertal development, while the risk of lower bone mass 
starts at mid-puberty when testicular function progressively declines, 
therefore mitigating the achievement of optimal peak bone mass. 
Lifestyle interventions (physical activity, smoking, diet, sun exposure), 
vitamin D and calcium supplementation and specific anti-osteoporotic 
drugs are required based on individual assessments of both BMD and 
fracture risk (Table 2). Aside from BMD, other microarchitecture fea-
tures of bone and bone strength have been described in KS using high-
resolution peripheral quantitated computed tomography (pQCT)156,157 
that allows better definition of bone structure and strength than DXA 
(which permits determination of bone density only). No trial has been 
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conducted in patients with KS on testosterone treatment using frac-
tures as primary endpoint. In addition, the effects of anti-osteoporotic 
drugs on BMD and fracture risk in KS have not been studied.
Psychological and psychiatric conditions/ Gender incongruence. 
Recommendations
38. We recommend considering psychosexual and psychiatric issues 
in all adult patients with KS and to induce consultation by a 
specialist if required (1,⊕⊕ ◯◯).
39. We suggest attention to the putative existence of gender incon-
gruence in patients with KS. The patient should then attend 
a respective specialist within a multidisciplinary setting (2,⊕ 
◯◯◯).
Evidence
The intellectual ability of KS might be mitigated in some cases, but 
not generally.125 Characteristic impairments of language skills, such 
as in verbal processing speed, expressive grammar as well as word 
retrieval have been reported.127 Patients with KS might have also 
exhibit impairments in executive functions related to attention, 
flexibility and planning as well as response inhibition.158 The risks 
of developing psychiatric conditions, such as schizophrenia, bipolar 
disorders, depression, anxiety, autism and ADHD are increased in 
patients with KS.159-163
Psychosexual development is often delayed and sexual problems 
might be more frequent in KS.164 Most patients identify as male, but 
gender incongruence in KS has been reported in some studies.72,165-173
Values
Attention to eventual psychological, sexual, psychiatric as well as 
gender incongruence aspects is suggested (Table 2). In patients 
with KS, a personality profile including lower levels of extraversion, 
insufficient emotional arousal, less openness and higher levels of 
neuroticism than in general is likely. Intelligence quotient scores are 
reported to be lower than average6,159 leading to poor socio-eco-
nomic status for many.
Remarks
The neurocognitive phenotype of patients with KS is highly variable. 
Many studies suffer from selection bias and the current knowledge 
of these aspects in KS is mainly based upon diagnosed cases. The 
non- diagnosed cases may present a more neutral phenotype and 
may not express problems to the same extent as diagnosed patient 
populations.
The presence of various degrees of gender incongruence will 
have an important impact when testosterone substitution ther-
apy is considered, as in such cases patients with KS may not wish 
for increased masculinization20,165-173 and aim for feminization. 
Interdisciplinary work up with mental health professionals will be 
mandatory.165-173 Feminizing hormone treatment might augment 
the risk for thrombosis, which is already increased in KS (see above).
3.4.5 | Risk of neoplasia
Recommendations
40. We recommend breast examination for patients with KS (in-
cluding mammary gland ultrasonography if necessary) for de-
tecting gynaecomastia at the first visit and then on an individual 
basis and eventual treatment as per guidelines (1,⊕⊕⊕◯).
Evidence
Patients with KS seem to have an increased mortality ratio for all can-
cers, especially regarding breast and lung cancer as well as non-Hodgkin 
lymphoma.137,138 The latter pathology exhibited an increased standard-
ized incidence ratio (SIR) of 3.02 in a large cohort of patients with KS.174 
Also various forms of leukaemia were found with an SIR 3.62 in this 
cohort (Ji et al. 2016). Nevertheless, a lower mortality from prostate 
cancer has been reported.137,138 Other studies demonstrated that pa-
tients with KS have an increased risk of breast cancer with a4-30-fold 
increased incidence compared with that in men with a karyotype of 
46,XY.41,135-138,175-177 The mean age of breast cancer in patients with 
KS is 58 years, which is earlier compared to men with a 46,XY karyotype 
(67 years).178 However, given the rarity of male breast cancer, the abso-
lute risk remains low for patients with KS. The calculated cumulative risk 
of occurrence by the age 75 years is 1%.136-138
Moreover, an increased incidence of extragonadal germ cell neoplasia 
in patients with KS, most commonly between an age of 15-30 years, has 
been reported. These tumours are located mainly within the mediastinum 
and are usually non-seminomas (mature teratomas or mixed tumours).179 
Clinically, younger boys may present precocious puberty due to hCG pro-
duction, while older patients present with thorax symptoms.180
A relationship between KS and testicular germ cell tumours is not 
documented.41,135-138,181,182 No cases of testicular germ cell neopla-
sia in situ (GCNIS) have been shown. The incidence of benign Leydig 
cell tumours in patients with KS has been reported higher than in the 
general population, although this may simply reflect a higher prev-
alence of Leydig cell hyperplasia rather than tumours. In a recent 
series, the frequency of Leydig cell tumours in KS does not seem 
higher than that found in infertile men.183,184
Values and Remarks
Patients with KS have an increased risk of some forms of neoplasia, 
especially breast cancer and mediastinal germ cell tumours (table 2). 
Physicians should be aware of the neoplasia risk in patients with KS 
so as not to lose the opportunity for early detection and treatment. 
The current epidemiological studies should be interpreted with cau-
tion, because of the generally low diagnostic rate of KS and small 
number of cohort longitudinal studies.
3.4.6 | Other disorders
Recommendations
41. We suggest clinical breast and axilla examinations every two 
years in adult patients with KS and eventual mammography 
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and/or mammary gland ultrasonography especially in those 
patients with a family history of breast cancer or other rea-
sons for suspicion thereof (1,⊕⊕◯◯).
42. We suggest ophthalmological assessments in patients with KS if 
the history points towards visual complaints (2,⊕◯◯◯).
43. We suggest examination of the dental status in patients with KS 
(2,⊕◯◯◯).
44. We suggest attention to possible autoimmune dysfunctions in 
patients with KS (2,⊕◯◯◯).
Evidence
Gynaecomastia has been recognized as part of the cardinal stig-
mata of KS since its first description.185,186 More recent studies 
have found gynaecomastia to be less common in KS, being present 
in about a third of adults, although prominent or persisting puber-
tal gynaecomastia remains an important sign of KS.122. Permanent 
gynaecomastia before and during pubertal transition is a clinical 
sign that should lead to suspicion of KS and eventual treatment, 
which should be surgical if required. The pathophysiology of gynae-
comastia may be due to unbalanced serum levels of testosterone 
and estradiol,15 but the length of the CAG repeat polymorphism of 
the AR gene and X chromosome inactivation status has been also 
suggested as factors of influence.6,9,142 The exact prevalence of KS 
among boys and adults with gynaecomastia is unknown, also be-
cause gynaecomastia itself is frequently undetected and clinicians 
often do not suspect KS when addressing gynaecomastia as this is a 
frequent complaint in adolescents in general. The EAA guideline on 
gynaecomastia should be consulted.187
There are reports on retinal dysfunction and impaired day vision/ 
night vision in KS.188,189 Development of teeth may be affected, imposing 
as taurodontism190 and an increased risk of caries has been reported.191-193 
Also, autoimmune disorders might be more frequent in KS,194-196 while 
thyroid functions do not seem to be affected in men with KS.197
Values and Remarks
Adequate diagnosis and, if required, treatment of gynaecomastia 
is paramount in KS in order to maintain self-esteem and a positive 
body image which are essential for patients’ mental health. The 
other conditions mentioned above should be diagnosed and treated, 
if possible (Table 2).
The reports on ophthalmologic, dental and autoimmune diseases 
are based on small numbers of patients with KS and need validation.
4  | GENER AL DEMANDS
4.1 | Recommendations
45. We recommend the set-up of multidisciplinary centres or 
structures to care for patients with KS (1,⊕⊕⊕◯).
46. We recommend improving the transitional care for patients 
with KS from paediatric to adult endocrinologists/andrologists 
(1,⊕⊕⊕◯).
47. We recommend improving knowledge about KS among doctors 
and society, especially by structured graduate and postgraduate 
education (1,⊕⊕⊕◯).
4.2 | Evidence
Actual data indicate that 21% of patients with KS are diagnosed pre-
natally, 10-12% during childhood, 16% at puberty and 51% during 
adulthood.19,172,198-200 Infants with KS usually present with a normal 
male phenotype; however, KS may be suspected in infants with bilat-
eral cryptorchidism and/or micro-penis.32-34,40,182,201-208
During childhood, speech and behavioural disturbances, exces-
sive growth as compared with parental predicted target height and 
abnormal body proportions may lead to a suspicion of KS.19 Delayed 
puberty, poor testicular development, gynaecomastia, excessive 
height, learning disabilities and psychosocial problems are symp-
toms that should cause suspicion of KS.20,65,172,204,205,209-212
Nevertheless, early diagnosis is quite rare but the increasing 
use of pre-natal tests will increase the number of patients with KS 
being diagnosed. This should be an advantage for the patient and a 
great opportunity to prevent possible associated comorbidities later 
in life.213-221 However, the empirical evidence that early diagnosis 
with subsequent intervention improves long-term adult outcomes is 
currently lacking.222-238 Physicians, especially paediatricians, should 
be aware of the relatively frequent incidence of KS and also the be-
havioural issues that might come with it.16,19,91,237 The information 
on KS and psychological support to the patient and his parents are 
of great importance for their confidence.222
4.3 | Values and Remarks
We put a high value on the recommendations to improve medical 
knowledge about KS among physicians and society in general.181,201 
It is also paramount to provide patients with KS and their parents 
with specific information and support them psychologically as 
needed. We also put a high value on the recommendation to the 
set-up of multidisciplinary centres for the care of patients with KS. 
These should include all professionals involved (geneticists, paedia-
tricians/paediatric endocrinologists, psychologists, speech thera-
pists, adult endocrinologists/andrologists, urologists, reproductive 
gynaecologists, sexologists, psychiatrists). EAA centres and other 
specialized centres within Europe and worldwide are recommended 
to serve as multidisciplinary units to be approached by KS patients 
and their physicians.
5  | CONCLUSIONS AND FUTURE 
DIREC TIONS
KS is the most common sex chromosomal disorder in men. It affects 
patients with both hypogonadism and infertility. In addition, men with 
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KS are afflicted with a higher risk of having cardiovascular, meta-
bolic, psychiatric and other comorbidities. Providing the patient with 
KS and, if deemed adequate, his parents with suitable and balanced 
information as well as assistance for various aspects of his life after 
receiving the diagnosis is suggested. Prevention and treatment of the 
medical complications and comorbidities associated with KS should be 
standardized as far as possible. Also minimizing neurodevelopmental 
dysfunction, that is verbal deficits, learning difficulties, behavioural 
problems should be aimed at. These measures are likely to promote 
the patients’ self-esteem, assure quality of life and improve his social 
adaption. Finally, preservation of the fertility potential, that is cryo-
preservation of spermatozoa from ejaculate or testicular tissue is an 
option now widely available.
The pathological conditions in patients with KS are most likely 
of a combined endocrine, genetic and epigenetic origin. Further 
research in a coordinated fashion is needed. KS is vastly underdi-
agnosed and an increment of general knowledge as well as establish-
ment of standard care in multidisciplinary networks is mandatory. 
These are the first guidelines to take a step towards this goal.
6  | LIST OF RECOMMENDATIONS AND 
SUGGESTIONS
6.1 | Genetic issues
1. We recommend that a pre-natal diagnosis of KS is confirmed on a 
chromosome analysis on peripheral blood postnatally (1, ⊕⊕⊕◯).
2. We recommend conventional karyotyping on peripheral blood 
cells for diagnosis of KS (1, ⊕⊕⊕◯).
3. We recommend that patients with KS and/or their parents are 
offered genetic counselling; pre-natal counselling should be non-
directive (1, ⊕⊕⊕◯).
4. We recommend karyotype analysis for detecting KS in men with 
non-obstructive azoospermia and (severe) oligozoospermia (total 
sperm count < 10 x 106/ejaculate or sperm concentration < 5 x 
106/ml (1, ⊕⊕⊕◯).
5. We recommend karyotype analysis for detecting KS in men with 
primary hypogonadism (low serum levels of testosterone) and 
elevated serum levels of gonadotropins (LH and FSH) combined 
with small testicular volumes (<5 ml per testis) (1, ⊕⊕⊕◯).
6.2 | CHILDREN AND PRE-PUBERTAL BOYS 
WITH KS
 6. We suggest karyotype analysis for detecting KS in boys 
born with cryptorchidism, especially the bilateral forms, who 
do not experience spontaneous descent of the testes at the 
first year (2, ⊕⊕◯◯).
 7. We recommend to treat cryptorchidism in children with KS 
according to the current treatment guidelines in children without 
KS (1, ⊕⊕⊕◯).
 8. We recommend general physical examinations in pre-pu-
bertal children with KS including a testicular evaluation. These 
should be performed biennially or as deemed as appropriate. 
Suspected neurological or psychiatric deficits should be examined 
by respective specialists (1, ⊕⊕⊕◯).
 9. We suggest determination of LH and testosterone during 
the first 2-3 months after birth in children with pre-natal diagnosis 
of KS when it might have a therapeutic consequence (ie diagnosis 
of micro-penis) (2, ⊕◯◯◯).
 10. We recommend against testicular tissue cryopreservation 
or spermatogonial stem cell retrieval in pre-pubertal children with 
KS (1, ⊕⊕⊕◯).
 11. We recommend against testosterone supplementation 
during early childhood in all patients with KS except in cases of 
micro-penis (1, ⊕⊕⊕◯).
 12. We suggest measurement of height according to centiles 
or standard deviation scores as well as body proportions and 
determinations of bone age in pre-pubertal children with KS de-
pending on individual growth patterns (2, ⊕⊕◯◯).
 13. We suggest determination of vitamin D blood levels and 
adequate vitamin D and calcium supplementation in pre-pubertal 
children with KS (2, ⊕◯◯◯).
 14. We suggest assessment of bone mineral status during 
childhood in case of vitamin D deficiency biennially in patients 
with KS (DXA scan, size-corrected determinations using a three-
step-method are required) (2, ⊕◯◯◯).
 15. We recommend measurement of weight using centiles or 
standard deviation scores in pre- pubertal children with KS (1, 
⊕⊕⊕◯).
 16. We recommend against testosterone treatment in infants 
and pre-pubertal boys with KS (1, ⊕⊕⊕◯).
 17. We recommend speech therapist control and therapy, 
monitoring learning disabilities, social training and psycho-
logical support, in pre-pubertal children with KS if needed (1, 
⊕⊕⊕◯).
6.3 | ADOLESCENTS WITH KS
 18. We recommend that information on fertility issues is 
given to adolescent patients with KS and, if deemed adequate, 
his parents. There is no level of recommendation, as this can 
be considered good clinical practice.
 19. We suggest testicular ultrasound during puberty of pa-
tients with KS and regularly at follow-up visits (2, ⊕◯◯◯).
 20. We suggest semen collection in adolescents with KS 
after careful information and assessment of the wish of the pa-
tient and cryopreservation if motile spermatozoa are present (2, 
⊕⊕◯◯).
 21. We suggest that adolescents with KS might undergo a tes-
ticular biopsy for testicular sperm extraction (TESE) either using 
multifocal (standard TESE) or microdissection-TESE (mTESE) and 
consequent sperm cryopreservation in selected cases requiring 
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specific counselling, provided their physical and mental maturity 
is apt for this decision (2, ⊕⊕◯◯).
 22. We recommend assessment of Tanner stages, pubertal 
development, measurement of testosterone and gonadotropins, 
signs and symptoms of hypogonadism, height, weight, waist cir-
cumference and body proportions starting prior to the predicted 
start of puberty in patients with KS and at individually determined 
intervals thereafter (the time-window for the start of puberty 
does not differ from boys with a karyotype of 46,XY) (1, ⊕⊕⊕◯).
 23. We recommend testosterone supplementation in case of 
delayed puberty and/or signs and symptoms of hypogonadism as-
sociated with low-normal testosterone and supra-normal LH serum 
concentrations (LH> 2 SD according to age-related references), after 
the fertility issues have been addressed (see above) (1, ⊕⊕⊕◯).
 24. We suggest against testosterone therapy in adolescents with 
KS with compensated hypergonadotropic hypogonadism (2, ⊕⊕◯◯).
 25. We recommend speech therapist control, monitoring edu-
cational problems, social training and psychological support in 
adolescents with KS, if needed (1 ⊕⊕⊕◯).
6.4 | ADULTS WITH KS
 26. We recommend initiation of testosterone substitution in 
patients with KS with hypogonadism as diagnosed according 
to established guidelines on hypogonadism, if possible once 
fertility issues have been addressed (1, ⊕⊕⊕◯).
 27. We recommend that testosterone substitution in patients 
with KS should follow the established guidelines on hypog-
onadism using the usually suggested monitoring intervals for clini-
cal assessment, safety parameters (haematocrit, PSA, other) and 
dose titration (1, ⊕⊕⊕◯).
 28. We recommend endocrine evaluation every 12 months in 
adult patients with KS who are not on testosterone substitution 
(1,⊕⊕◯◯).
 29. We recommend semen analysis and sperm cryopreservation 
in all adult patients with KS and a wish for paternity (1, ⊕⊕⊕◯).
 30. We recommend that all adult patients with KS and con-
firmed azoospermia and a current or putative future wish for 
paternity undergo a testicular biopsy for testicular sperm extrac-
tion (TESE) either using multifocal (standard TESE) or microdis-
section-TESE (mTESE) and consequent sperm cryopreservation 
(1, ⊕⊕⊕◯).
 31. We suggest against starting testosterone replacement 
therapy in patients with KS when a TESE is planned, due to the 
possible suppression of gonadotropins and further suppression of 
remnant spermatogenesis (2, ⊕⊕◯◯)
 32. We recommend education on lifestyle and yearly assess-
ment of weight, waist circumference, blood pressure, fasting 
glucose, HbA1c and lipid profile and adequate treatment in all pa-
tients with KS (1, ⊕⊕⊕◯).
 33. We suggest thrombosis prophylaxis prior to long-term 
flights or exposure to other risks in patients with KS to attenuate 
the increased risk for deep vein thrombosis and/or pulmonary 
embolism (2, ⊕⊕⊕◯).
 34. We suggest assessment of 12-lead ECG QTc time at least 
once in patients with KS (2, ⊕⊕⊕◯)
 35. We recommend following the EAA clinical guidelines on 
management of bone health in the andrological outpatient clinic, 
bearing in mind that patients with KS are at risk of low bone min-
eral density (BMD) and fractures independently of their serum 
levels of testosterone (1, ⊕⊕⊕◯).
 36. We recommend DXA analysis at the lumbar and fem-
oral levels and fracture risk assessment at the first visit of 
adult patients with KS and then on an individual basis (1, 
⊕⊕◯◯).
 37. We suggest determination of vitamin D plasma levels 
in all adult patients with KS at the first visit and then on an 
individual basis, independently from their BMD, and proper 
vitamin D and calcium supplementation when needed (2, 
⊕⊕◯◯).
 38. We recommend considering psychosexual and psychiatric 
issues in all adult patients with KS and to induce consultation by a 
specialist if required (1, ⊕⊕◯◯).
 39. We suggest attention to the putative existence of gender 
incongruence in patients with KS. The patient should then at-
tend a respective specialist within a multidisciplinary setting (2, 
⊕◯◯◯) (2, ⊕◯◯◯).
 40. We recommend breast examination for patients with 
KS (including mammary gland ultrasonography if necessary) 
for detecting gynaecomastia at the first visit and then on an 
individual basis and eventual treatment as per guidelines (1, 
⊕⊕⊕◯).
 41. We suggest clinical breast and axilla examinations every 
two years in adult patients with KS and eventual mammography 
and/or mammary gland ultrasonography especially in those pa-
tients with a family history of breast cancer or other reasons for 
suspicion thereof (1, ⊕⊕◯◯).
 42. We suggest ophthalmological assessments in patients with 
KS if the history points towards visual complaints (2, ⊕◯◯◯).
 43. We suggest examination of the dental status in patients 
with KS (2, ⊕◯◯◯).
 44. We suggest attention to possible autoimmune dysfunc-
tions in patients with KS (2, ⊕◯◯◯).
6.5 | GENERAL DEMANDS
45. We recommend the set-up of multidisciplinary centres or struc-
tures to care for patients with KS (1, ⊕⊕⊕◯).
46. We recommend improving the transitional care for patients with 
KS from paediatric to adult endocrinologists/andrologists (1, 
⊕⊕⊕◯).
47. We recommend improving knowledge about KS among doctors 
and society, especially by structured graduate and postgraduate 
education (1, ⊕⊕⊕◯).
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